Blatt has more than 29 years of drug research and development experience with a specific focus on biology of the immune system, infectious diseases, antiviral therapies, and relevant therapeutic interventions.
Until recently, he was the global head of infectious diseases and vaccines at Johnson and Johnson. He founded Alios BioPharma, which developed therapies for viral diseases, including respiratory syncytial virus and hepatitis C.
Prior to Alios, he was chief scientific officer of InterMune. He also held successive positions as vice president of research of Sirna/Ribozyme Therapeutics, vice president of product development at National Genetics Institute, and product development team leader, interferons at Amgen.
Blatt achieved a Ph.D. in public health administration from the University of La Verne and completed his MBA from California State University, Northridge.
Privately held Meissa Vaccines is developing vaccines to prevent viral respiratory infections. It is focused on the advancement of vaccines for respiratory syncytial virus and rhinovirus. The company is also developing vaccines for parainfluenza virus and human metapneumovirus.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer